occurr
coronaviru
diseas
case
wuhan
citi
hubei
provinc
china
firstli
emerg
decemb
newli
identifi
novel
coronaviru
formerli
known
caus
pneumoniaassoci
respiratori
syndrom
analysi
genom
sequenc
sampl
obtain
differ
infect
patient
share
high
sequenc
ident
sarscov
compar
sarscov
transmit
humantohuman
seem
greater
februari
least
countri
report
case
infect
patient
infect
show
typic
pneumonia
sever
lung
damag
diagnos
either
clinic
ct
radiographi
laboratori
real
time
revers
transcriptionpolymeras
chain
reaction
rtpcr
unfortun
specif
antivir
drug
vaccin
current
sever
approach
suggest
control
infect
includ
vaccin
monoclon
antibodi
oligonucleotid
peptid
interferon
smallmolecul
drug
antibodymedi
humor
respons
crucial
prevent
viral
infect
subset
antibodi
reduc
viral
infect
bind
surfac
epitop
viral
particl
therebi
block
entri
viru
infect
cell
defin
neutral
antibodi
nab
nab
elicit
protect
activ
three
main
step
nab
may
prevent
attach
virion
receptor
target
cell
caus
aggreg
viru
particl
virus
lyse
constant
c
region
antibodymedi
opson
complement
activ
review
focus
understand
immunopathogenesi
address
benefit
challeng
consider
neutral
antibodi
nab
shown
figur
major
structur
protein
includ
spike
membran
envelop
e
nucleic
capsid
n
protein
coronaviru
initi
cell
fusion
via
attach
protein
receptor
host
cell
surfac
viral
nucleocapsid
deliv
insid
subsequ
replic
protein
compris
two
unit
receptorbind
domain
rbd
within
directli
interact
host
receptor
structur
function
analysi
show
protein
bind
angiotensinconvert
enzym
receptor
human
alveolar
epitheli
cell
suggest
use
receptor
sarscov
howev
protein
bind
higher
affin
sarscov
high
affin
protein
human
may
lead
great
humantohuman
transmiss
due
key
role
protein
main
target
antibodymedi
neutral
clinic
spectrum
outcom
highli
variabl
mild
flulik
symptom
sever
pneumonia
critic
take
insight
cellular
humor
respons
elucid
immunopathogenesi
use
develop
passiv
antibodi
therapi
design
vaccin
understand
clinic
drug
intervent
howev
system
landscap
immun
respons
patient
unclear
clinic
featur
immunopathogenesi
pose
similar
sarscov
knowledg
learn
sarscov
import
implic
understand
new
coronaviru
resist
sarscov
infect
associ
innat
adapt
immun
respons
innat
immun
respons
sarscov
complet
defin
studi
demonstr
macrophag
dendrit
cell
dc
play
import
role
viral
destruct
immun
respons
induct
mucosalassoci
lymphoid
tissu
due
homeostasi
macrophag
dc
vehicl
seem
dissemin
virus
effer
lymphat
system
meanwhil
activ
dc
macrophag
sarscov
led
excess
proinflammatori
cytokin
respons
drastic
elev
inflammatori
cytokin
chemokin
observ
tissu
serum
sarscov
patient
level
gener
enhanc
earli
infect
subsequ
reduc
recoveri
stage
uncontrol
system
inflamm
known
cytokin
storm
result
ill
sever
similar
symptom
cytokin
storm
observ
infect
inflammatori
cytokin
chemokin
may
lead
activ
cell
respons
upregul
howev
patient
secret
excess
may
suppress
inflamm
via
differ
sarscov
infect
studi
necessari
elucid
innat
respons
pathogenesi
adapt
immun
respons
mainli
consist
cellular
cell
humor
b
cell
respons
cellmedi
respons
sarscov
infect
well
elucid
tcell
provid
broad
longterm
protect
cell
promot
prolifer
neutral
antibodi
wherea
cell
respons
destruct
viral
infect
cell
although
surfac
protein
includ
e
n
protein
involv
cell
respons
protein
contribut
tcell
recognit
epitop
overal
frequenc
cell
respons
predomin
cell
respons
lymphopenia
occur
sarscov
infect
reduct
cell
commonli
associ
lymphopenia
interest
elucid
tcell
mediat
respons
infect
may
provid
import
hint
design
vaccin
compos
viral
structur
protein
hand
patient
sarscov
infect
strong
humor
immun
respons
sarscov
serum
igg
igm
iga
respons
sarscov
appear
patient
primari
sar
infect
neutral
igg
play
major
role
neutral
sarscov
igg
reach
peak
serum
convalesc
phase
diminish
recoveri
memori
b
cell
still
provid
longterm
protect
associ
cellular
immun
respons
despit
markedli
reduc
viru
replic
anti
protein
neutral
igg
could
associ
fatal
acut
lung
injuri
promot
product
inflammatori
macrophag
accumul
studi
may
provid
import
implic
observ
igg
respons
patient
nab
provid
import
specif
immun
defens
viral
infect
patient
number
antivir
nab
develop
recent
year
clinic
develop
role
import
nab
protect
sarscov
infect
thoroughli
review
elsewher
entri
sarscov
host
cell
mediat
attach
protein
receptor
protein
major
induc
nab
particularli
rbd
within
unit
critic
target
sarscov
nab
nab
interrupt
interact
rbd
receptor
nab
identifi
recogn
rbd
region
interestingli
nab
still
show
recogn
epitop
unit
suggest
mechan
could
involv
neutral
last
viru
clearanc
mediat
antibodydepend
opson
complement
activ
nab
sarscov
summar
tabl
phage
display
use
identifi
neutral
human
monoclon
antibodi
sarscov
immun
antibodi
librari
select
antibodi
block
bind
domain
show
viru
neutral
prophylaxi
capabl
either
vitro
anim
model
although
show
much
neutral
alon
mixtur
show
neutral
sarscov
synergist
effect
due
recognit
differ
epitop
rbd
method
epsteinbarr
viru
ebv
transform
human
b
cell
use
isol
nab
six
group
nab
divid
base
differenti
neutral
sarscov
variant
success
identifi
memori
b
cell
sarscov
infect
patient
furthermor
transgen
mice
human
immunoglobulin
gene
use
produc
nab
sarscov
antigen
immun
two
nab
identifi
transgen
mice
effect
viru
prophylaxi
anim
model
hand
sever
nab
epitop
sarscov
still
show
effect
neutral
simplest
direct
approach
combat
outbreak
would
use
plasma
convalesc
patient
polyclon
nab
could
induc
convalesc
patient
effect
treat
nab
provid
passiv
immun
respons
viral
infect
inde
sar
ebola
patient
receiv
treatment
convalesc
plasma
howev
outcom
passiv
plasma
therapi
unpredict
due
variabl
sera
differ
patient
develop
nab
rel
rapid
approach
obtain
standard
agent
control
reemerg
protein
like
import
target
develop
nab
block
bind
fusion
figur
seem
use
cell
entri
receptor
sarscov
show
bind
rbd
sarscov
howev
recent
studi
demonstr
protein
bind
higher
affin
sarscov
suggest
recognit
could
differ
sarscov
although
show
high
homolog
sarscov
antibodi
crossreact
limit
two
viru
protein
sever
publish
sarscov
nab
appreci
bind
protein
recent
studi
show
sarscov
antibodi
bind
rbd
neutral
capabl
uncertain
cocktail
nab
show
stronger
neutral
alon
treatment
ebola
sar
virus
find
suggest
cocktail
antibodi
approach
could
undertaken
therefor
meaning
gener
nab
target
differ
epitop
combin
sever
potent
nab
could
decreas
probabl
escap
viru
isol
decreas
sensit
neutral
comput
simul
antibodyantigen
complex
use
guid
design
therapeut
antibodi
number
antibodi
structur
current
around
deposit
avail
protein
data
bank
pdb
base
pdb
data
compar
model
antibodi
onto
viral
surfac
antigen
predict
key
residu
rbd
nab
identifi
provid
import
implic
vaccin
key
residu
interfac
antibodi
antigen
optim
produc
high
affin
sever
recent
comput
dock
model
use
predict
interact
protein
human
antibodi
studi
reveal
import
discoveri
sarscovspecif
antibodi
could
crossreact
avail
therapeut
nab
offer
benefit
control
current
pandem
possibl
reemerg
viru
futur
develop
therefor
remain
high
prioriti
effort
nab
develop
sure
area
intens
research
come
month
even
year
current
sever
strategi
use
clinic
develop
viraltarget
therapeut
hosttarget
agent
interferon
glucocorticoid
treatment
compar
therapeut
strategi
nab
appear
specif
virion
understand
action
mechan
nab
may
provid
valuabl
implic
rapid
develop
antibodi
therapi
vaccin
howev
develop
nabbas
therapeut
timeconsum
labori
process
date
nab
agent
either
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
avail
market
meanwhil
note
caution
effect
antibodi
immun
respons
protect
pulmonari
pathogenesi
sarscov
controversi
patient
die
sar
show
strong
nab
respons
pulmonari
proinflammatori
accumul
suggest
nab
could
associ
fatal
acut
lung
injuri
therefor
import
take
insight
humor
cellular
respons
antivir
immunotherapi
develop
